M&A Deal Summary

Hikma Pharmaceuticals Acquires Teligent - Sterile Injectable Assets

On January 17, 2022, Hikma Pharmaceuticals acquired life science company Teligent - Sterile Injectable Assets from Teligent for 46M USD

Acquisition Highlights
  • This is Hikma Pharmaceuticals’ 4th transaction in the Life Science sector.
  • This is Hikma Pharmaceuticals’ 3rd largest (disclosed) transaction.
  • This is Hikma Pharmaceuticals’ 1st transaction in Canada.
  • This is Hikma Pharmaceuticals’ 1st transaction in Ontario.

M&A Deal Summary
Date 2022-01-17
Target Teligent - Sterile Injectable Assets
Sector Life Science
Buyer(s) Hikma Pharmaceuticals
Sellers(s) Teligent
Deal Type Divestiture
Deal Value 46M USD

Target

Teligent - Sterile Injectable Assets

Mississauga, Ontario, Canada
Teligent's Sterile Injectable Assets includes a portfolio of 25 sterile injectable products, three in-licensed ophthalmic products, and a pipeline of seven additional products. Teligent's Sterile Injectable Assets are based in Mississauga, Ontario.

Search 193,381 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Hikma Pharmaceuticals

London, United Kingdom

website

Category Company
Founded 1978
Sector Medical Products
Employees8,800
Revenue 2.5B USD (2022)
DESCRIPTION

Hikma Pharmaceutical is a developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. Hikma Pharmaceuticals was founded in 1978 and is based in London, the United Kingdom.

DEAL STATS #
Overall 10 of 10
Sector (Life Science) 4 of 4
Type (Divestiture) 1 of 1
State (Ontario) 1 of 1
Country (Canada) 1 of 1
Year (2022) 1 of 1
Size (of disclosed) 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-09-27 Custopharm

Carlsbad, California, United States

Custopharm is a generic injectable drug services company. The company specializes in developing a range of generic injectable products, including those with complex formulations. Custopharm also offers regulatory consulting services to help customers with drafting and filing abbreviated new drug applications (ANDAs). Custopharm was formed in 2005 and is based in Carlsbad, California.

Buy $375M

Seller(S) 1

SELLER

Teligent

Buena, New Jersey, United States

website

Category Company
Founded 1977
Sector Life Science
Employees252
Revenue 66M USD (2019)
DESCRIPTION

Teligent manufactures, fills and packages topical semi?solid and liquid products for cosmetic, cosmeceutical and pharmaceutical customers. Teligent’s products are used for cosmetic, cosmeceutical and prescription applications for the treatment of symptoms of dermatitis, acne, psoriasis, and eczema. Teligent was founded in 1977 and is based in Buena, New Jersey.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Ontario) 1 of 1
Country (Canada) 1 of 1
Year (2022) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-11-16 Alveda Pharmaceuticals

Toronto, Ontario, Canada

Alveda Pharmaceuticals, Inc. is specializing in the sale and distribution of quality pharmaceuticals. Alveda Pharmaceuticals was founded in Toronto, Ontario.

Buy CA$47M
Mergr

Product

Company

Legal